
The FDA approves zanidatamab for HER2-positive biliary cancer, improving treatment options.
The FDA approves zanidatamab for HER2-positive biliary cancer, improving treatment options.
The significant surge in oncology drug shortages in 2023 particularly affected essential chemotherapeutic drugs.